Zhao Zeyu, Chu Meijie, Guo Yichao, Yang Shiting, Abudurusuli Guzainuer, Frutos Roger, Chen Tianmu
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.
CIRAD, Intertryp, Montpellier, France.
Front Microbiol. 2022 Jun 2;13:884598. doi: 10.3389/fmicb.2022.884598. eCollection 2022.
Hepatitis C imposes a heavy burden on many countries, including China, where the number of reported cases and the incidence of hepatitis C virus (HCV) increased yearly from 2005 to 2012, with a stable trend after 2012. The geographical distribution of HCV infections varies widely in China, with the northwest and southwest regions and the Henan Province showing a high disease burden. Elderly, men, sexually active people, drug users, migrants, blood transfusion recipients, and renal dialysis patients have become the target populations for hepatitis C prevention and control. It is important to improve the diagnosis rate in high-risk groups and asymptomatic people. Identifying secondary HCV infections, especially in HCV patients co-infected with the human immunodeficiency virus (HIV) is a priority of hepatitis C prevention and control. Enhancing universal access to direct antiviral agents (DAAs) treatment regimens is an effective way to improve the cure rate of HCV infection. For China to contribute to the WHO 2030 global HCV elimination plan, strategic surveillance, management, and treatment program for HCV are needed.
丙型肝炎给包括中国在内的许多国家带来了沉重负担。在中国,2005年至2012年期间报告的丙型肝炎病例数和丙型肝炎病毒(HCV)发病率逐年上升,2012年后呈稳定趋势。HCV感染在中国的地理分布差异很大,西北地区、西南地区和河南省疾病负担较高。老年人、男性、性活跃人群、吸毒者、移民、输血受者和肾透析患者已成为丙型肝炎防控的目标人群。提高高危人群和无症状人群的诊断率很重要。识别继发性HCV感染,尤其是在同时感染人类免疫缺陷病毒(HIV)的HCV患者中,是丙型肝炎防控的重点。扩大直接抗病毒药物(DAAs)治疗方案的普及是提高HCV感染治愈率的有效途径。为使中国能够为世界卫生组织2030年全球消除丙型肝炎计划做出贡献,需要制定HCV的战略监测、管理和治疗方案。